ELF Score: Non-Invasive Biomarker for MASH Liver Fibrosis
ELF (Enhanced Liver Fibrosis) score: FDA-approved non-invasive biomarker from HA, PIIINP, TIMP-1. Algorithm, cutoffs, and role in MASH trials.
1. Why the ELF Score Matters
Liver biopsy has long been the gold standard for assessing hepatic fibrosis. Yet it carries intrinsic limitations: invasiveness, sampling error (only ~1/50,000 of the liver is captured), and inter-observer variability. In MASH (metabolic dysfunction-associated steatohepatitis) trials, repeating biopsies once or twice per year places an unrealistic burden on patients.
Against this backdrop, non-invasive serum biomarkers for fibrosis have advanced rapidly. Among them, the ELF (Enhanced Liver Fibrosis) Score stands out for:
- FDA clearance (2021, Siemens Healthineers ADVIA Centaur ELF test) as one of the few prognostic biomarkers approved for this purpose
- Endorsement in the AASLD 2018 guidance and EASL 2024 guidelines
- Applicability across chronic liver disease broadly — not just MASH/NAFLD but also PBC and HCV
This article reviews ELF's derivation, clinical cutoffs, and its utility from preclinical through clinical MASH drug development.
2. Components and Algorithm
The ELF score integrates three serum biomarkers reflecting extracellular matrix (ECM) turnover.
Constituent Biomarkers
| Biomarker | Role | Source / Metabolism |
|---|---|---|
| HA (Hyaluronic Acid) | ECM glycosaminoglycan | Secreted by activated hepatic stellate cells (HSCs) |
| PIIINP (Procollagen III N-terminal Peptide) | Fibrogenesis marker | Cleaved during type III collagen synthesis |
| TIMP-1 (Tissue Inhibitor of Metalloproteinase-1) | MMP inhibitor | Blocks ECM degradation, promotes accumulation |
All three reflect the activity of hepatic stellate cells and myofibroblasts activated via the TGF-β/Smad pathway.
Formula
ELF = -7.412 + 0.681 × ln(HA) + 0.775 × ln(PIIINP) + 0.494 × ln(TIMP-1)
- Concentrations in ng/mL
- Logarithmic transformation linearizes the scale across mild to advanced fibrosis
- Automated on dedicated analyzers (ADVIA Centaur XP/XPT)
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. Clinical Cutoffs and Interpretation
NICE/NAFLD Guidance (UK)
| ELF Score | Interpretation | Action |
|---|---|---|
| < 7.7 | No/mild fibrosis | Observation |
| 7.7 – 9.7 | Moderate fibrosis (~F2) | Lifestyle intervention, treatment consideration |
| 9.8 – 10.50 | Advanced fibrosis (~F3) | Specialist referral |
| ≥ 10.51 | Severe fibrosis/cirrhosis (F3-F4) | Active treatment |
FDA Clearance (2021) — Prognostic Use
The FDA cleared ELF ≥ 9.8 as a predictor of liver-related events (liver failure, hepatocellular carcinoma, transplant, liver-related death) in chronic liver disease.
Comparison with Other Biomarkers
| Indicator | Strengths | Limitations |
|---|---|---|
| ELF | FDA-cleared, prognostic, works across fibrosis stages | Requires dedicated analyzer, higher cost |
| FIB-4 | Free (age, AST, ALT, platelets) | Low specificity for advanced fibrosis (F3-F4) |
| Pro-C3 | MASH-specific, reflects de novo ECM synthesis | Not yet standardized, no reimbursement |
| FibroScan (VCTE) | Imaging-based, immediate results | Reduced reliability with obesity/ascites |
Clinical practice is converging on a two-step approach: FIB-4 for screening → ELF/FibroScan for confirmation.
Clinical Perspective: ELF as a FibroScan Alternative
Hepatologists note that FibroScan (VCTE) offers superior diagnostic accuracy, but the dedicated device is not available at every institution. Because ELF requires only a blood sample and can be processed via central laboratories, it is broadly adopted at primary- and community-care levels across Europe and North America, particularly where FibroScan is unavailable. In the UK, NICE guidance positions ELF as a standard primary-care tool for NAFLD risk stratification.
4. Role of ELF in MASH Drug Development
Trial Enrollment Criterion
For trials targeting advanced fibrosis (F2-F3), ELF ≥ 9.8 is increasingly used as an enrollment criterion because:
- Biopsy-based identification of F2-F3 suffers high false-negative rates from sampling error
- ELF-based pre-screening sharply lowers biopsy-failure dropouts
- Adopted in flagship trials including Resmetirom (MAESTRO-NASH) and Semaglutide (ESSENCE)
Use as an Endpoint
FDA and EMA are evaluating ELF improvement as a surrogate endpoint. Multiple cohort studies show ELF change correlates with histological fibrosis stage change, opening the possibility of accelerated-approval pathways.
Related reading:
- Resmetirom (Rezdiffra) — Mechanism and Trials
- MASH Therapeutics Landscape 2025
- MASLD/MASH Biomarkers Comprehensive Guide
5. Use in Preclinical Research
ELF itself is not used in animal studies, but measuring its individual components is valuable in several preclinical contexts.
HA (Hyaluronic Acid)
- Serum HA tracks fibrosis progression in CCl4-induced models and MASH dietary models
- Straightforward ELISA detection (Echelon Biosciences and others)
PIIINP
- Reflects new collagen synthesis — a useful early efficacy signal for anti-fibrotic compounds
- Often combined with Pro-C3
TIMP-1
- Indicator of impaired ECM degradation — rises during fibrosis progression, falls during resolution
- Also tracks with macrophage activation
Constructing a "mouse ELF" Surrogate
In mice, measuring all three serum components and correlating them with hydroxyproline content or Sirius Red-stained area allows non-invasive longitudinal efficacy assessment.
6. FAQ
Q1: Can ELF be measured in Japan?
As of 2026, no insurance reimbursement exists in Japan, but self-pay measurement via ADVIA Centaur is available at select academic centers and MASH trial sites. BioPredictive's "FibroMeter" and similar non-invasive scores are also available domestically.
Q2: Should I use ELF or FIB-4?
FIB-4 for screening (free, simple); ELF for confirmation and prognosis. FIB-4 tends to underestimate F3+ disease, and in MASH specifically, combining both provides the most reliable readout.
Q3: Does ELF work in other liver diseases like HCV and PBC?
Yes. The original ELF study (Rosenberg 2004) validated the score across 1,021 patients including HCV, ALD, and PBC — it is disease-agnostic within chronic liver disease.
Q4: Does treatment improve ELF?
Phase 3 trials including Resmetirom's MAESTRO-NASH have reported significant ELF reductions with anti-MASH therapy. However, the magnitude is more modest than histological stage improvement, and ≥6 months of observation is recommended.
Q5: Why measure ELF components in preclinical models?
Serum HA/PIIINP/TIMP-1 in mice enables longitudinal assessment of the same animal — ELF's greatest preclinical strength. Combined with terminal histology (Sirius Red), you can dissect the temporal phase of compound action (early vs. late).
Related Articles
- FIB-4 Score Complete Guide — Formula, age-stratified cutoffs, AASLD/EASL recommendations, FIB-4 + ELF two-step strategy
- MASLD/MASH Biomarkers Guide — Comprehensive coverage including FIB-4, Pro-C3, ELF
- Fibrosis Biomarkers Comprehensive Guide — Cross-organ biomarker overview
- Resmetirom (Rezdiffra) — Real-world example of ELF-guided trial design
- MASH Therapeutics Landscape 2025 — Full pipeline view
- Compensated vs Decompensated Cirrhosis: MASH Endpoint Guide — HVPG, MELD 3.0, Child-Pugh, and decompensation-prevention endpoints
- MASH Model Selection Guide — Preclinical model decision matrix
- TGF-β/Smad Pathway — Master regulator and ECM machinery
References
- Rosenberg WM, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127(6):1704-1713. PMID: 15578508
- Parkes J, et al. Enhanced Liver Fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59(9):1245-1251. PMID: 20675693
- Vali Y, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2020;73(2):252-262. PMID: 32275982
- Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PMID: 38324483
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. PMID: 36727674
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2021;75(3):659-689. PMID: 34166721